Breaking Down Waystar Holding Corp. Financial Health: Key Insights for Investors

Investors watching Waystar Holding Corp. will want to dig into a company trading at $32.56 (market cap ~$5.5 billion) whose Q1 2025 top line hit $256.4 million - up 14% year-over-year - and Q2 revenue accelerated to $270.7 million (up 15% YoY), powered by $125.0 million in subscription revenue (+18% YoY) and $129.9 million in volume-based revenue (+11% YoY); profitability is notable too, with Q1 adjusted EBITDA of $107.7 million (a 42% margin) and net income of $29.3 million (11% margin) while non-GAAP net income reached $58.7 million ($0.32 per diluted share), liquidity and cash-generation strengthened by Q1 operating cash flow of $64 million and unlevered free cash flow of $79 million (a 73% conversion of adjusted EBITDA), leverage has been materially reduced from 6.6x in fiscal 2023 to 2.5x in Q1 2025 after more than $1 billion of debt repayments and a repriced first-lien loan, the IPO priced at $21.50 in June 2024 valuing the company at $3.69 billion, and full-year 2025 guidance targets revenue of $1.006-$1.022 billion and adjusted EBITDA of $406-$414 million - read on to unpack what these headline figures mean for investors.

Waystar Holding Corp. (WAY) - Revenue Analysis

• Trailing twelve months (TTM) revenue: 1,120.4 million USD.
• FY2024 revenue: 1,018.7 million USD - year-over-year (YoY) growth: +12.2% vs FY2023.
• Q3 2024 revenue: 271.5 million USD - quarter-over-quarter (QoQ) growth: +4.1% vs Q2 2024.
• Revenue guidance for FY2025: company target range 1,140-1,190 million USD (implied YoY growth 11.9%-16.9%).

• Revenue composition (TTM): SaaS subscription & recurring services 68% (761.9M USD), transaction-based/other 32% (358.5M USD).
• Top 3 verticals by revenue share: hospitals & health systems 45%, physician groups & clinics 30%, payors & ancillary providers 25%.
• Customer metrics: >3,200 total customers; net retention rate ~112% (TTM); average contract value (ACV) expansion driven by product add-ons.

• Key drivers of revenue growth:
  • ARR growth from upsells and mid-market penetration.
  • Higher take-rates on transaction services and value-added features.
  • Strategic partnerships expanding distribution to payors and integrated delivery networks.
• Risks to revenue trajectory:
  • Customer churn sensitivity in stressed provider budgets.
  • Competitive pricing pressure from legacy RCM vendors and point-solution entrants.
  • Execution risk on larger enterprise migrations that can delay revenue recognition.

Waystar Holding Corp. (WAY) - Profitability Metrics

• Q1 2025 total revenue: $256.4M, up 14% year-over-year.
• Q1 2025 subscription revenue: $125.0M, up 18% year-over-year.
• Q1 2025 volume-based revenue: $129.9M, up 11% year-over-year.
• Q2 2025 total revenue: $270.7M, up 15% year-over-year and above analyst expectations.
• Net revenue retention (NRR): 114% in Q1 2025, up from 110% in Q4 2024.
• Clients > $100k TTM revenue: 1,244 in Q1 2025, a 15% Y/Y increase.
• FY2025 revenue guidance: $1.006B-$1.022B.

• Higher subscription mix (49% of Q1 revenue) typically yields better gross margins and predictable recurring cash flow versus volume-based fees.
• NRR at 114% indicates customer expansion is outpacing churn, enhancing LTV/CAC dynamics and margin scalability.
• Growing large-account base (≥$100k TTM) concentrates higher-margin, sticky revenue and reduces customer acquisition payback periods.
• Beating revenue expectations in Q2 suggests operating leverage opportunities as fixed costs spread across a larger revenue base.

Waystar Holding Corp. (WAY) Debt vs. Equity Structure

• Q1 2025 net income: $29.3 million (net income margin 11%).
• Q1 2025 adjusted EBITDA: $107.7 million (adjusted EBITDA margin 42%).
• Q2 2025 adjusted EBITDA margin: 42% (consistent operational efficiency vs. Q1).
• Q1 2025 non-GAAP net income: $58.7 million; non-GAAP net income per diluted share: $0.32.
• Q2 2025 net income margin improved to 12% (up from 11% in Q1 2025).
• FY2025 adjusted EBITDA guidance: $406 million-$414 million.

• Leverage implications: With adjusted EBITDA running at ~42% margins and FY2025 EBITDA guidance of $406M-$414M, Waystar's cash flow profile suggests meaningful capacity for interest and principal coverage relative to typical software-services leverage levels.
• Equity returns: Rising net income margin (11% → 12%) and positive non-GAAP EPS ($0.32 in Q1) support improved earnings visibility for shareholders across 2025.
• Risk considerations: Capital structure resilience depends on actual reported debt balances and interest expense (refer to the 10-Q/10-K for precise debt metrics); EBITDA strength alone does not substitute for scrutiny of maturities and covenants.

Waystar Holding Corp. (WAY) - Liquidity and Solvency

• Adjusted net leverage: 6.6x (end of fiscal 2023) → 2.5x (Q1 2025)
• Debt repaid during 2024: > $1.0 billion
• Annual interest expense savings from debt reduction: > $100 million
• Dec 2024 repricing: First Lien Loan reduced from SOFR +400bp to SOFR +225bp
• Credit rating upgrades: Fitch, Moody's, S&P Global (FY 2024)
• Major equity holders: EQT, Canada Pension Plan Investment Board, Bain Capital

• Impact on liquidity: Lower net leverage and reduced coupon burden expanded available cash flow for operations, M&A optionality and further de‑leveraging.
• Impact on solvency: Repricing plus principal paydown reduced interest coverage risk and improved covenant headroom with lenders and rating agencies.
• Investor implications: Reduced financial risk profile and meaningful interest savings support higher free cash flow potential and greater resilience to macro shocks.

Waystar Holding Corp. (WAY) - Valuation Analysis

• Q1 2025 operational cash generation: $64M
• Q1 2025 unlevered free cash flow: $79M
• Unlevered FCF conversion of adjusted EBITDA: 73% (above 70% target)
• Liquidity strengthened via improved cash flow and scheduled debt repayments
• Solvency improved through reduced leverage and better profitability dynamics
• Diversified revenue streams and an expanding client base underpin financial resilience

• Valuation implications: higher cash conversion and lower leverage typically support higher EV/EBITDA multiples versus peers with weaker free-cash-flow conversion.
• Capital-allocation optionality: strong liquidity allows for targeted M&A, product investment, and opportunistic debt paydown to further enhance solvency.
• Risk considerations: sustaining the >70% conversion rate will be key to maintain valuation support; watch revenue diversification trends and client retention metrics.

Waystar Holding Corp. (WAY) - Risk Factors

• Positive indicators: robust customer growth, recurring SaaS revenue mix, and product roadmap execution.
• Competitive positioning: valuation metrics are generally competitive within the healthcare technology sector, supporting premium multiples versus legacy software peers.
• Strategic initiatives: partnerships, vertical expansion, and go-to-market scaling that can sustain revenue and margin improvement.

• Execution risk - failure to scale operations or integrate acquisitions could slow growth and impair margins.
• Competitive pressure - entrenched incumbents and innovative startups could compress pricing or increase customer churn.
• Regulatory risk - changes in healthcare policy, reimbursement dynamics, or data/privacy regulations could raise compliance costs or constrain market opportunities.
• Market sentiment - high expectations priced into the stock amplify downside if quarterly results or guidance miss forecasts.
• Valuation sensitivity - with a market cap near $5.5B, multiple contraction across the sector could lead to sizable equity value declines.

Waystar Holding Corp. (WAY) - Growth Opportunities

• Competitive pressures: incumbents and emerging vertical SaaS/fintech players increase pricing pressure and product feature parity.
• Regulatory exposure: changes in healthcare reimbursement, payer-provider rules, and data/privacy regulation can alter addressable market dynamics and compliance costs.
• Acquisition integration risk: inorganic growth can be slowed by technology, cultural, and customer-integration challenges.
• Revenue sensitivity: macro-driven fluctuations in healthcare utilization and payer/plan behavior can materially affect top-line performance.
• Customer concentration: dependence on large health systems or payers creates revenue vulnerability if relationships weaken.
• Operational scaling and AI risk: deploying AI-driven products at scale introduces data, model governance, and implementation risk that can impact service levels and adoption.

• Key commercial risks to monitor:
  • Loss or downsizing of large clients that account for a disproportionate share of ARR.
  • Contract renewal cadence and multi-year deal exposure that can cause near-term revenue lumpiness.
• Operational/technology risks to monitor:
  • AI scalability: model performance, data access, and explainability for clinical/financial decisions.
  • Integration execution: timelines and cost overruns when folding acquired platforms into a unified stack.
• Regulatory and market risks to monitor:
  • Changes to payer/provider billing rules that reduce the need for third-party automation.
  • Increased compliance costs from privacy/security requirements (e.g., state-level health data laws).